Pregnancy outcomes among African-American patients with systemic lupus erythematosus compared with controls

April Barnado,1 Lee Wheless,2 Anna K Meyer,1 Gary S Gilkeson,1 Diane L Kamen1

ABSTRACT

Objective: In a study of Gullah African-Americans, we compared pregnancy outcomes before and after systemic lupus erythematosus (SLE) diagnosis to controls to test whether there is a predisease state that negatively affects pregnancy outcomes.

Design: Cases and controls reporting at least one pregnancy were included. Controls were all Gullah African-American females. We collected demographic, socioeconomic and pregnancy data. We modelled pregnancy outcome associations with case status using multiple logistic regression to calculate ORs.

Results: After adjustment for age, years of education, medical coverage and pregnancy number, compared with controls, cases were more likely to have any adverse outcome (OR 2.35, 95% CI 1.78 to 3.10), including stillbirth (OR 4.55, 95% CI 1.53 to 13.50), spontaneous abortion (OR 2.05, 95% CI 1.40 to 3.00), preterm birth (OR 2.58, 95% CI 1.58 to 4.20), low birth weight (OR 2.64, 95% CI 1.61 to 4.34) and preeclampsia (OR 1.80, 95% CI 1.08 to 3.01). The odds of adverse pregnancy outcomes all increased after SLE diagnosis compared with before diagnosis, even after adjustment for age, years of education, pregnancy number and medical coverage.

Conclusion: From a large cohort of African-American women, our findings suggest there may be a predisease state that predisposes to adverse pregnancy outcomes.

KEY MESSAGES

▸ Among a unique African American cohort, there is an increased risk of adverse pregnancy outcomes in SLE cases both before and after SLE diagnosis compared with controls.
▸ There may be a predisease state in SLE that negatively impacts pregnancy outcomes and may not be entirely antibody mediated.

INTRODUCTION

Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with a strong female predominance. African-Americans have a threefold increased prevalence of SLE, develop SLE at an earlier age and have increased SLE-related morbidity and mortality compared with Caucasians.1–3 SLE diagnosis is associated with adverse pregnancy outcomes with an increased risk of preeclampsia, preterm live birth, low birth weight, spontaneous abortion (SAB) and stillbirth.6–14 However, the question of whether there is a difference between outcome risk before versus after diagnosis of SLE has not been well studied in an African-American cohort. Previous studies have examined adverse pregnancy outcomes with respect to timing of disease onset, but only a few of those studies used a control group.5–7,9 These studies were limited by low number of pregnancies after SLE diagnosis,7,9 and only one investigated rates of preeclampsia before and after SLE diagnosis.9

Using data from a large, well-characterised case–control study of Gullah African-Americans, we compared pregnancy outcomes before and after SLE diagnosis to healthy controls. Our study population consisted of an African-American Gullah population of the Sea Islands of South Carolina with a proven homogeneous genetic and environmental background.15,16 A high prevalence of multipatient families with SLE,17 and a distinct cultural identity.18 By examining pregnancy outcomes before and after SLE diagnosis, this study was conducted to explore whether there is a predisease state that negatively affects pregnancy outcomes.

PATIENTS AND METHODS

This research was carried out in compliance with the Helsinki Declaration with the approval of the Institutional Review Board at the Medical University of South Carolina. Data for this study were analysed retrospectively from information collected from study

[Additional content continues...]

To cite: Barnado A, Wheless L, Meyer AK, et al. Pregnancy outcomes among African–American patients with systemic lupus erythematosus compared with controls. Lupus Science & Medicine 2014;1:e000020. doi:10.1136/lupus-2014-000020

Accepted 28 March 2014

Revised 25 March 2014

Received 29 January 2014

Correspondence to
Dr Diane L Kamen; kamend@musc.edu

LUPUS SCIENCE & MEDICINE™

1Division of Rheumatology, Department of Medicine, Medical University of South Carolina, Charleston, South Carolina, USA
2Department of Public Health Sciences, Medical University of South Carolina, Charleston, South Carolina, USA

14 However, the question of whether there is a difference between outcome risk before versus after diagnosis of SLE has not been well studied in an African-American cohort. Previous studies have examined adverse pregnancy outcomes with respect to timing of disease onset, but only a few of those studies used a control group.5–7,9 These studies were limited by low number of pregnancies after SLE diagnosis,7,9 and only one investigated rates of preeclampsia before and after SLE diagnosis.9

Using data from a large, well-characterised case–control study of Gullah African-Americans, we compared pregnancy outcomes before and after SLE diagnosis to healthy controls. Our study population consisted of an African-American Gullah population of the Sea Islands of South Carolina with a proven homogeneous genetic and environmental background.15,16 A high prevalence of multipatient families with SLE,17 and a distinct cultural identity.18 By examining pregnancy outcomes before and after SLE diagnosis, this study was conducted to explore whether there is a predisease state that negatively affects pregnancy outcomes.

PATIENTS AND METHODS

This research was carried out in compliance with the Helsinki Declaration with the approval of the Institutional Review Board at the Medical University of South Carolina. Data for this study were analysed retrospectively from information collected from study
visits that were part of a longitudinal observational cohort called SLE in Gullah Health (SLEIGH), which was started in 2002. A more complete description of the cohort has been previously reported. Briefly, eligible cases were (1) age 2 years and above, (2) self-identified as African-American ‘Gullah’ from the Sea Island region of South Carolina, (3) diagnosed with SLE by meeting at least 4 of the 11 classification criteria as designated by the American College of Rheumatology (ACR), (4) able to speak and understand English and (5) able and willing to give informed consent. SLE cases were asked to bring family members and friends from the Gullah community, who were unaffected by SLE, to a study visit for recruitment as potential controls. Controls included in this study were confirmed not to have SLE using a screening interview, examination and laboratory testing. Classification as Gullah required that the subjects self-identify and confirm that parents and grandparents were of Gullah heritage with no known ancestors that were not of Gullah lineage.

Of the 888 participants in the SLEIGH cohort, analyses were restricted to African-American Gullah female cases and controls reporting at least one pregnancy. Demographic, socioeconomic and pregnancy data were collected. Pregnancy outcomes were self-reported with adverse events confirmed by chart review. Stillbirth was defined as pregnancy loss at or after 22 weeks, and SAB was defined as less than 5 pounds, 8 ounces and median birthweight of disease with less than 5 pounds. In the time of study design, the WHO and International Classification of Disease defined stillbirth as greater than 22 weeks. Low birth weight was defined as less than 5 pounds, 8 ounces and preterm live birth as delivery before 37 weeks. Preeclampsia was self-reported based on questions asked by a physician and included “Did you experience high blood pressure during this pregnancy?” If the subject answered yes, then the subsequent question asked was “Did your doctor diagnose you with preeclampsia or eclampsia?” If the subject answered yes or was not sure of the answer, a chart review was performed. Preeclampsia was not further classified as mild or severe for this study. Stillbirth and SAB were grouped as fetal loss for secondary analyses. Stillbirth, SAB, low birth weight, preterm live birth and preeclampsia were grouped as any adverse pregnancy outcome for secondary analyses. Medical coverage was defined as receiving healthcare reimbursements from private insurance, Medicaid, Medicare or military benefits. Disability was defined as currently receiving disability payments. Cumulative damage was measured using the Systemic Lupus International Collaborating Clinics/ACR Damage Index (SDI). SDI was considered a dichotomous variable, no damage versus any damage.

Antibody serologies including double-stranded DNA (ds-DNA), SSA, SSB, anticardiolipin antibody (aCL), antibody to β2-glycoprotein I (anti-β2GPI) and lupus anticoagulant (LAC) were examined. Baseline measures of SSA, SSB and aCL were done with methods for antibody determination previously described. ds-DNA, anti-β2GPI and LAC were done at a local laboratory at the Medical University of South Carolina. Anti-β2GPI and ds-DNA was tested using an enzyme-linked immunosorbent assay. LAC was tested using a dilute Russell’s viper venom time with confirmatory studies. aCL and anti-β2GPI were considered high-titre positive if IgG or IgM titres were ≥40 units and low-titre positive if IgG or IgM titres were ≥20 units and <40 units.

Categorical variables were examined by χ² tests. Differences in the means of continuous variables were compared using Student t tests. Pregnancy outcome associations were modelled with case status using multiple logistic regression to calculate ORs and 95% CIs. Covariates included age, years of education, medical coverage, age at the time of pregnancy and pregnancy number. Pregnancy number was defined as order of the pregnancy, not total number of pregnancies. For example, the third pregnancy in a woman with five pregnancies would be coded as three. Elective abortion, preterm birth, low birth weight and preeclampsia were each modelled as separate outcomes. All analyses were conducted using SAS V.9.1 (SAS Institute, Cary, North Carolina, USA). Two-sided p values ≤0.05 were considered significant.

| Characteristics | SLE cases (n=220) | Controls (n=217) | p Value* |
|-----------------|------------------|-----------------|----------|
| Mean age (years)±SD | 48.1±12.4 | 54.3±13.4 | <0.01 |
| Mean age (years) at first pregnancy±SD | 22.1±5.0 | 22.1±5.8 | 0.95 |
| Mean years of education±SD | 12.1±1.9 | 12.1±2.1 | 0.96 |
| Medical coverage† (%) | 82.7 | 86.6 | 0.26 |
| Disability‡ (%) | 38.6 | 6.9 | <0.01 |
| Employment (%) | 32.3 | 71.9 | <0.01 |
| Prenancies±SD | 2.6±1.4 | 3.2±2.1 | <0.01 |
| Live births±SD | 2.3±1.2 | 2.8±1.9 | <0.01 |

*χ² test.
†Includes private insurance, Medicare, Medicaid and military benefits.
‡Currently receiving disability payments.
SLE, systemic lupus erythematosus.
RESULTS

Characteristics of cases (n=220) and controls (n=217) are compared in Table 1. Compared with controls, cases were significantly younger (48.1 vs 54.3, p<0.01) at time of data analysis with similar mean years of education (12.1 vs 12.1, p=0.96). Cases had similar medical coverage compared with controls (82% vs 87%, p=0.26), but were significantly more likely to be unemployed (68% vs 28%, p<0.01) and to receive disability payments at time of study enrolment (39% vs 7%, p<0.01). Mean age at first pregnancy was similar in cases versus controls (22 vs 22, p=0.95), and 58% of pregnancies in cases occurred before diagnosis. Compared with controls, cases had significantly fewer pregnancies (2.6 vs 3.2, p<0.01) and live births (2.3 vs 2.8, p<0.01). Cases had fewer pregnancies after SLE diagnosis compared with before (0.7 vs 1.5, p<0.01). Cases had fewer live births after SLE diagnosis compared with before (0.4 vs 1.2, p<0.01). Mean age at SLE diagnosis was 33.0±11.7 years. Duration of disease at time of diagnosis was 14.5±8.4 years. Cases fulfilled a mean of 6.1±1.9 ACR criteria (Table 2). Cases had a mean SDI of 2.3±1.9, with 82% having any damage.

Pregnancy outcomes in cases before and after SLE diagnosis compared with controls are detailed in Table 3. Of the pregnancies in the control group, 19.1% resulted in adverse outcomes compared with 34.4% before SLE diagnosis and 51.7% after SLE diagnosis. Where the date of diagnosis or pregnancy was unknown, 39.8% of these pregnancies resulted in adverse outcomes. After adjustment for age, years of education, medical coverage and pregnancy number, compared with controls, cases were more likely to have any adverse outcome (OR 2.35, 95% CI 1.78 to 3.10), including stillbirth (OR 4.55, 95% CI 1.53 to 13.50), SAB (OR 2.05, 95% CI 1.40 to 3.00), preterm birth (OR 2.58, 95% CI 1.58 to 4.20), low birth weight (OR 2.64, 95% CI 1.61 to 4.34) and preeclampsia (OR 1.80, 95% CI 1.08 to 3.01). Cases and controls had similar rates of elective abortion.

Table 2 ACR criteria of African-American Gullah female SLE cases

| ACR criterion               | % cases (n=220) |
|------------------------------|-----------------|
| Malar rash                   | 51.7            |
| Discoid rash                 | 33.5            |
| Photosensitivity             | 56.7            |
| Oral/nasal ulcers            | 43.2            |
| Arthritis                    | 86.4            |
| Serositis                    | 42.6            |
| Renal disorder               | 50.3            |
| Neurologic disorder          | 18.2            |
| Hematologic disorder         | 59.8            |
| Immunologic disorder         | 78.0            |
| Antinuclear antibody positivity | 98.1         |

ACR, American College of Rheumatology; SLE, systemic lupus erythematosus.

Table 3 ORs and 95% CIs for adverse pregnancy outcomes occurring before and after SLE diagnosis compared with controls in an African-American population

|                  | Controls (694 pregnancies) | Cases (337 pregnancies) | Cases (before diagnosis) | Cases (after diagnosis) | Cases (unknown order) |
|------------------|-----------------------------|-------------------------|--------------------------|-------------------------|-----------------------|
| Stillbirth       | 1.00 (reference)            | 1.00 (reference)        | 1.00 (reference)         | 1.00 (reference)        | 1.00 (reference)      |
| Spontaneous abortion | 1.02 (reference)         | 2.20 (1.30 to 3.39)*   | 0.92 (0.58 to 1.46)*    | 2.79 (1.64 to 4.78)*   | 2.46 (1.50 to 3.90)*  |
| Elective abortion | 0.99 (reference)            | 1.13 (0.58 to 2.20)*   | 1.31 (0.65 to 2.63)*    | 0.99 (0.50 to 1.96)*   | 0.99 (0.50 to 1.88)*  |
| Preterm live birth | 1.00 (reference)            | 1.00 (0.36 to 2.36)†   | 0.63 (0.21 to 1.89)†    | 1.07 (0.36 to 3.54)†   | 1.00 (0.63 to 1.61)†  |
| Low birth weight  | 1.00 (reference)            | 2.58 (1.43 to 4.32)*   | 1.37 (0.87 to 2.12)*    | 1.97 (1.07 to 3.64)†   | 1.04 (0.66 to 1.64)†  |
| Preeclampsia     | 1.00 (reference)            | 1.80 (0.98 to 3.40)*   | 1.14 (0.57 to 2.28)*    | 1.42 (0.70 to 2.89)*   | 1.04 (0.66 to 1.64)†  |

All estimates are adjusted for age, years of education, insurance and pregnancy number.

*p<0.05.
†Unadjusted model.
SLE, systemic lupus erythematosus.
Pregnancies before diagnosis were more likely to end in any adverse outcome (OR 2.23, 95% CI 1.66 to 2.99) compared with controls. Those pregnancies occurring after diagnosis (OR 4.55, 95% CI 3.13 to 6.62) and those with an unknown order of occurrence (OR 2.81, 95% CI 1.78 to 4.43) were more strongly associated with any adverse outcome compared with controls. After adjustment for age, years of education, pregnancy number and medical coverage, the odds of SAB (OR 2.50, 95% CI 1.40 to 4.45), preterm birth (OR 2.94, 95% CI 1.51 to 5.74) and low birth weight (OR 2.98, 95% CI 1.54 to 5.80) all increased after SLE diagnosis compared with before diagnosis. Stillbirth (OR 1.34, 95% CI 0.39 to 4.59), elective abortion (OR 1.15, 95% CI 0.32 to 4.15) and preeclampsia (OR 1.11, 95% CI 0.51 to 2.44) did not increase after SLE diagnosis compared with before diagnosis.

In univariate models, age at first birth (OR 1.07, 95% CI 1.01 to 1.14, p=0.03), age at the time of pregnancy (OR 1.05, 95% CI 1.02 to 1.08, p<0.01), years of education (OR 1.14, 95% CI 1.05 to 1.23, p<0.01), currently working (OR 0.71, 95% CI 0.52 to 0.98, p=0.03) and disability (OR 1.48, 95% CI 1.03 to 2.11, p=0.03) were all associated with fetal loss. In adjusted models, among both cases and controls, age, age at first birth, mean years of education, employment and disability were not associated with fetal loss, elective abortion, preterm birth, low birth weight or preeclampsia.

Using SLE cases with pregnancies after diagnosis, disease duration prior to pregnancy was not associated with fetal loss (OR 1.04, 95% CI 0.94 to 1.14), elective abortion (OR 0.75, 95% CI 0.44 to 1.29), preterm birth (OR 1.07, 95% CI 0.95 to 1.21), low birth weight (OR 1.07, 95% CI 0.95 to 1.21) or preeclampsia (OR 1.05, 95% CI 0.92 to 1.20). Among pregnancies after SLE diagnosis, none of the individual ACR criteria were associated with adverse pregnancy outcomes, nor was SDI associated with fetal loss (OR 2.30, 95% CI 0.67 to 7.90), elective abortion (OR 0.38, 95% CI 0.05 to 3.02), preterm birth (OR 1.59, 95% CI 0.36 to 7.00), low birth weight (OR 3.92, 95% CI 0.69 to 22.22) or preeclampsia (OR 0.60, 95% CI 0.12 to 2.87).

Rates of antibody positivity in pregnancies with and without adverse outcomes in African-American SLE females are shown in table 4. Pregnancies occurring in mothers positive for SSA were significantly more likely to end in adverse outcomes (37.4% vs 22.8%, p=0.048) as well as for pregnancies occurring in mothers positive for SSB (12.9% vs 7.0%, p=0.02) compared with pregnancies in mothers negative for these antibodies. Pregnancies with mothers having any SLE-related antibody approached significance for association with any adverse pregnancy outcome (75.7% vs 68.7%, p=0.07).

ORs for adverse pregnancy outcomes both before and after SLE diagnosis in SLE cases with antibody positivity are shown in table 5. In unadjusted analyses, ds-DNA positivity was associated with preeclampsia (OR 2.18, 95% CI 1.07 to 4.43) and approached significance for low birth weight (OR 1.70, 95% CI 0.93 to 3.12) but was not associated with other adverse pregnancy outcomes. SSA positivity was significantly associated with premature live births (OR 2.27, 95% CI 1.28 to 4.02), low birth weight (OR 2.12, 95% CI 1.17 to 3.85) and approached significance for any adverse outcome (OR 1.47, 95% CI 1.00 to 2.17). SSB positivity was significantly associated with premature live birth (OR 3.89, 95% CI 1.77 to 8.58), low birth weight (OR 2.91, 95% CI 1.24 to 6.82) and any adverse outcome (OR 1.96, 95% CI 1.09 to 3.53). Having any SLE-related antibody was associated with preeclampsia (OR 4.52, 95% CI 1.58 to 12.91) and approached significance for any adverse outcome (1.43, 95% CI 0.98 to 2.08). aCL positivity was associated with a decreased risk of preeclampsia (OR 0.21, 95% CI 0.05 to 0.89). LAC and anti-β2GPI were not associated with any adverse pregnancy outcomes. Low numbers of adverse pregnancy outcomes precluded stratifying analyses by pregnancies occurring before and after SLE diagnosis or adjusting for covariates.

**DISCUSSION**

Among a large cohort of African-American women, we observed significantly higher rates of adverse pregnancy outcomes in cases both before and after diagnosis of SLE compared with controls. The risk of adverse pregnancy outcomes further increased after SLE diagnosis. Three prior studies have investigated pregnancy outcomes before and after SLE diagnosis using control groups. Two of these studies had predominantly African-American patients with SLE and found increased adverse pregnancy outcomes both before and after SLE diagnosis compared with control groups. However, one study

### Table 4 Rates of antibody positivity in pregnancies with and without adverse outcomes in African-American SLE females

| Antibody Agreement | Any adverse pregnancy outcome* (% (n)) | No adverse pregnancy outcome (% (n)) | p Value |
|-------------------|--------------------------------------|-------------------------------------|--------|
| ds-DNA            | 59.7 (135)                           | 57.5 (200)                          | 0.59   |
| SSA               | 37.4 (66)                            | 22.8 (73)                           | 0.048  |
| SSB               | 12.9 (28)                            | 7.0 (22)                            | 0.02   |
| aCL               |                                      |                                     | 0.27   |
| Low titre        | 7.1 (13)                             | 11.5 (29)                           |        |
| High titre       | 8.2 (15)                             | 9.5 (24)                            |        |
| anti-β2GPI Low    | 6.7 (7)                              | 10.7 (16)                           | 0.55   |
| anti-β2GPI High   | 3.9 (4)                              | 3.3 (5)                             |        |
| LAC               | 16.3 (23)                            | 14.8 (31)                           | 0.69   |
| Any SLE-related   | 75.7 (171)                           | 68.7 (239)                          | 0.07   |

*Includes stillbirth, spontaneous abortion, low birth weight, preterm birth and preeclampsia. Anti-β2GPI, antibody to β2-glycoprotein I; LAC, lupus anticoagulant; SLE, systemic lupus erythematosus.
| Antibody positivity          | Stillbirth OR (95% CI) | Spontaneous abortion OR (95% CI) | Elective abortion OR (95% CI) | Premature live birth OR (95% CI) | Low birth weight OR (95% CI) | Preeclampsia OR (95% CI) | Any adverse outcome OR (95% CI) |
|-----------------------------|------------------------|----------------------------------|-----------------------------|-------------------------------|--------------------------|--------------------------|-------------------------------|
| ds-DNA                     | n=11                   | 1.54 (0.53 to 4.50) p=0.43        | 0.77 (0.50 to 1.19) p=0.24   | 1.50 (0.60 to 3.75) p=0.39    | 1.16 (0.67 to 1.99) p=0.60 | 1.70 (0.93 to 3.12) p=0.09 | 2.18 (1.07 to 4.43) p=0.03  |
| SSA                        | n=4                    | 0.98 (0.31 to 3.12) p=0.98        | 1.14 (0.69 to 1.87) p=0.61   | 1.18 (0.45 to 3.12) p=0.74    | 2.27 (1.28 to 4.02) p<0.01 | 2.12 (1.17 to 3.85) p=0.01  | 1.61 (0.82 to 3.15) p=0.17  |
| SSB                        | n=1                    | 0.70 (0.09 to 5.41) p=0.73        | 1.47 (0.73 to 2.95) p=0.28   | 1.16 (0.26 to 5.19) p=0.85    | 3.89 (1.77 to 8.58) p<0.01 | 2.91 (1.24 to 6.82) p=0.01  | 1.49 (0.54 to 4.12) p=0.44  |
| Lupus anticoagulant        | n=3                    | 1.52 (0.41 to 5.71) p=0.53        | 0.83 (0.37 to 1.88) p=0.65   | 1.60 (0.50 to 5.11) p=0.43    | 1.53 (0.66 to 3.51) p=0.32 | 0.91 (0.33 to 2.53) p=0.86  | 1.39 (0.56 to 3.47) p=0.48  |
| Anticardiolipin*           | n=2                    | 0.69 (0.15 to 3.14) p=0.63        | 1.22 (0.68 to 2.21) p=0.51   | 0.90 (0.25 to 3.20) p=0.43    | 0.52 (0.21 to 1.30) p=0.16 | 0.43 (0.15 to 1.26) p=0.12  | 0.21 (0.05 to 0.89) p=0.03  |
| Anti-β2GPI*                | n=2                    | 1.52 (0.31 to 7.56) p=0.61        | 0.40 (0.12 to 1.37) p=0.14   | 0.61 (0.08 to 4.95) p=0.87    | 0.63 (0.18 to 2.24) p=0.47 | 1.70 (0.57 to 5.06) p=0.34  | 1.53 (0.47 to 4.99) p=0.48  |
| Any SLE-related antibody   | n=14                   | 2.98 (0.67 to 13.31) p=0.15       | 1.23 (0.75 to 2.01) p=0.41   | 1.14 (0.44 to 2.97) p=0.79    | 1.23 (0.68 to 2.24) p=0.50 | 1.44 (0.75 to 2.80) p=0.28  | 4.52 (1.58 to 12.91) p<0.01 |

All estimates are unadjusted.

*Includes both low and high titres.

Anti-β2GPI, antibody to β2-glycoprotein I; SLE, systemic lupus erythematosus.
found that risk of pregnancy loss was not significantly different before and after SLE diagnosis, but that risk of therapeutic abortion increased after SLE diagnosis compared with before.\(^9\) Notably, the SLE cases in this one study were predominantly white in contrast to other studies in the literature and our current study.\(^6\) We found similar rates of pregnancy loss, combining SAB and stillbirth, of 14.8% before SLE diagnosis and 29.9% after SLE diagnosis, while Petri and Allbritton found 19% before SLE and 27% after SLE diagnosis.\(^6\) In addition, rates of preterm pregnancies were similar at 8.9% before and 17.7% after SLE diagnosis compared with 6% before and 24% after SLE diagnosis in Petri and Allbritton.\(^6\)

A limitation in our study is that our cohort was not comprised of incident cases; therefore, many patients were diagnosed with SLE before enrolling into the cohort. As much as possible, physician records were obtained to confirm cases’ reports of date of diagnosis. In addition, some cases were truly diagnosed with SLE after their pregnancies. In our cohort, less than 10% of SLE cases were diagnosed after age 50, which is consistent with published rates of late-onset SLE, decreasing the likelihood that there was an over-representation of pregnancies classified as occurring before diagnosis.\(^23\) In addition, with a retrospective design, there was potential for recall bias in subjects reporting pregnancy outcomes. Our study may also under-represent early pregnancy loss as often not reported, and data collection did not include questions assessing for pregnancy loss at less than 10 weeks. For the low birth weight outcome, we included questions assessing for pregnancy loss at less than 10 weeks. For the low birth weight outcome, we found no significant associations of LAC with pregnancy loss and aCL or anti-β\(_2\)GPI.\(^26\) In a meta-analysis of patients with SLE, the presence of a positive LAC or aCL was associated with preeclampsia and premature birth.\(^27\) In another meta-analysis that excluded women with autoimmune disease, aCL was significantly associated with severe preeclampsia more so than mild preeclampsia.\(^28\) Our analyses did not find these associations as there were few adverse pregnancy outcomes that occurred after SLE diagnosis in cases with available antibodies. In the absence of serial measurements to determine exact date of seroconversion of antibodies, no inferences regarding etiologic associations of antibodies to pregnancy outcomes can be drawn from these data. Although aCL was protective against preeclampsia in this study, this finding was based on two individuals positive for aCL having preeclampsia and is likely a spurious association.

Prior studies have shown increased adverse pregnancy outcomes associated with SSA and SSB positivity.\(^29\) In our unadjusted analyses, pregnancies occurring in mothers with SSA and SSB positivity were significantly more likely to end in adverse outcomes. SSA and SSB were both associated with premature live birth and low birth weight. However, other studies did not show significant associations between SSA and SSB positivity and adverse pregnancy outcomes.\(^6\)\(^8\)\(^12\)

There was a significant association of ds-DNA positivity with preeclampsia. This finding has been previously reported with hypotheses that ds-DNA antibodies may be pathogenic to the fetus.\(^2\)\(^3\)\(^20\)\(^21\)\(^22\)\(^23\)\(^24\) In addition, prior literature reports that SLE antibodies cluster with specific clinical manifestations.\(^33\)\(^34\) ds-DNA has been reported to cluster with renal disease.\(^33\)\(^34\) which could explain the association between ds-DNA positivity and increased risk of preeclampsia. In another study, ds-DNA positivity was associated with a higher rate of pregnancy loss and preterm birth in the second trimester and even further increased risk in the setting of high disease activity.\(^35\)

A number of demographic characteristics, such as age at pregnancy, were associated with adverse outcomes in univariate models. However, these became non-significant in adjusted models, likely due to low numbers of adverse events. Other studies in the literature focus on association of race and education with adverse pregnancy outcomes with one study investigating social class.\(^6\)\(^8\)\(^9\)\(^12\) However, there were no studies looking specifically at employment and disability status, as performed in our analysis. Our analyses showed that current disability and unemployment were both associated with a history of fetal loss.

In our study, there was an increased risk of fetal loss with increasing years of education. Our findings are in contrast with others who observed an inverse association between education and adverse outcomes.\(^6\)\(^8\) Specifically, one study observed a significant association between preterm birth and non-high school graduates.\(^6\) Another study found fewer years of education was associated with
adverse pregnancy outcomes, which pooled miscarriages, stillbirths, premature birth and therapeutic abortions. Our results likely differ due to different outcomes used in the analysis and due to low numbers of adverse outcomes limiting the ability to adjust for confounders.

Increased risks of adverse pregnancy outcomes in SLE cases have been consistently observed in multiple cohorts. Identification of factors associated with these risks could lead to improved understanding of the underlying mechanism, but also aid in counselling patients on their pregnancy risk. In our study, there was not an association among mean disease duration and SDI and adverse pregnancy outcomes. Other similar cohort studies did not investigate disease duration or SDI. For renal outcomes, there was no significant association of adverse pregnancy outcomes and ACR renal criterion, although low power limited the ability to detect this association. One similar cohort study found that renal involvement, defined as fulfilling ACR renal criterion or biopsy-proven SLE nephritis, was associated with adverse pregnancy outcomes, a composite of miscarriages, stillbirth, premature birth and therapeutic abortions. A meta-analysis of pregnancy outcomes in SLE nephritis cases showed active SLE nephritis was associated with increased risk of premature birth and history of nephritis was associated with higher rates of preeclampsia.

There was no association between any of the ACR criteria and adverse pregnancy outcomes. One cohort study found a higher number of ACR criteria fulfilled at diagnosis were associated with adverse pregnancy outcomes. Notably, this study used a multiethnic cohort of SLE cases with disease duration 5 years or less. Another study did not observe an association between any specific ACR criterion and adverse pregnancy outcomes. In addition, prior studies have investigated complement levels and their association with pregnancy outcomes with mixed results. While one study did not show a significant association with low serum complement levels and pregnancy loss and preterm birth, two other studies did show that decreased serum levels of C3 were associated with pregnancy loss and intrauterine growth restriction. However, it is noted that complement levels may fluctuate in normal pregnancies and may not correlate with disease activity in pregnant patients with SLE. In response to these concerns, one study showed that low complement levels, especially in the setting of high SLE activity, were associated with increased fetal loss and preterm delivery in the second trimester. In our study, complement levels were measured at the study visits. However, the majority did not have this information during pregnancies, so we were unable to comment on association of complement levels to pregnancy outcomes.

Strengths of this study included a high sample size for SLE cases, controls and number of pregnancies. Our study included controls that allowed for comparison to other cohorts in the literature. Moreover, our cohort consisted of a unique African-American population with similar genetic and environmental backgrounds. Cases and controls were both drawn from the same unique cohort, which allowed for direct comparisons of pregnancy outcomes with high internal validity.

Our study had a number of limitations. Similar to other studies, there were a low number of adverse outcomes limiting power to address confounding thoroughly. With a retrospective analysis, there were missing dates on comorbid conditions that limited the ability to determine associations with adverse pregnancy outcomes. Although disease activity, as measured by SLE Disease Activity Index (SLEDAI), and medication use were obtained at the study visits, the majority did not have this information before or during pregnancies, so we were unable to comment on the contribution of disease activity and medications to adverse pregnancy outcomes. Further, many of the pregnancies occurred approximately 20–30 years ago with less knowledge in the management of high-risk pregnancies and treatment options for SLE. This may have contributed to slight over-representation of adverse outcomes. Our population was restricted to African-American Gullah females with SLE and controls, and so our results from this specific population may not be generalisable to the broader population.

Among a unique cohort of African-American Gullah females with at least one pregnancy, we observed an increased risk of adverse pregnancy outcomes in SLE cases compared with controls both before and after SLE diagnosis. These increased risks remained after adjusting for age, years of education, insurance status and pregnancy number. These findings agree with prior studies in the literature and argue for the presence of a predilection state that could negatively impact pregnancy outcomes. SSA and SSB positivity were associated with adverse pregnancy outcomes, whereas we did not find this association with LAC or anti-β2GPI. While autoantibodies have been shown to play a role in the risk of adverse pregnancy outcomes, there remain other important disease factors that are also contributing to this risk. Additional prospective studies are needed to understand and characterise risk and protective factors associated with pregnancy outcomes among patients with SLE to guide counselling and future interventions.

**Contributors** All authors were involved in drafting the article or revising its content, and all authors approved the final version to be published. AB, LW and DLK had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Study conception and design: AB, GG and DLK. Acquisition of data: AKM, GG and DLK. Analysis and interpretation of data: AB, LW and DLK.

**Funding** This work has been supported by funding from the National Institutes of Health: Medical University of SC Clinical and Translational Science Award UL1 RR029882 (GG, DLK), NIGMS grant T32GM008716 (GW) and National Institute of Arthritis and Musculoskeletal and Skin Diseases grants P60 AR062755 (GG, DLK) and K23 AR052264 (DLK).

**Competing interests** None.
REFERENCES

1. Alarcón GS, McGwin G Jr, Bastian HM, et al. Systemic lupus erythematosus in three ethnic groups. VII [correction of VIII]. Predictors of early mortality in the LUMINA cohort. LUMINA Study Group. *Arthritis Rheum* 2001;45:191–202. Erratum in: *Arthritis Rheum* 2001;45:306.

2. Ward MM, Studenski S. Clinical manifestations of systemic lupus erythematosus. *Lupus* 1998;4:1173–80.

3. Dooley MA, Hogan S, Jennette C, et al. Systemic lupus erythematosus in three ethnic groups: II. Features predictive of disease activity earlier in its course. LUMINA Study Group. Lupus in minority populations, nature versus nurture. *Arthritis Rheum* 1998;41:1173–80.

4. Wye MM, Guss M. Incidence of and risk factors for hospitalization in systemic lupus erythematosus: a prospective study of the Hopkins Lupus Cohort. *J Rheumatol* 1992;19:1559–65.

5. Hardy CJ, Palmeter BM, Morton SJ, et al. Systemic lupus erythematosus in three ethnic groups: clinical manifestations of systemic lupus erythematosus. *Arch Intern Med* 1990;150:849–53.

6. Petri M. High-risk factors for hospitalization in systemic lupus erythematosus: a prospective study of the Hopkins Lupus Cohort. *J Rheumatol* 1993;20:650–6.

7. Dhar JP, Essenmacher LM, Ager JW, et al. Pregnancy outcomes in women with systemic lupus erythematosus from a multiethnic US cohort: LUMINA (LVI). *Obstet Gynecol* 2008;112:268–73.

8. Alarcón GS, Roseman J, Bartolucci AA, et al. Fetal outcome of lupus pregnancy: a retrospective case-control study of the Hopkins Lupus Cohort. *Arch Intern Med* 1993;20:650–6.

9. Lockshin MD, Kim M, Laskin CA, et al. Prediction of adverse pregnancy outcome by the presence of lupus anticoagulant, but not anticardiolipin antibody, in patients with antiphospholipid antibodies. *Arthritis Rheum* 2012;64:2311–18.

10. Smyth A, Oliveira GH, Lahr BD, et al. A systematic review and meta-analysis of pregnancy outcomes in patients with systemic lupus erythematosus and lupus nephritis. *Clin J Am Soc Nephrol* 2010;5:2060–8. [Review]

11. Petri M, Albrightson J. Fetal outcome of lupus pregnancy: a retrospective case-control study of the Hopkins Lupus Cohort. *J Rheumatol* 2001;28:183–90.

12. Nili F, McLeod L, O’Connell C, et al. Maternal and neonatal outcomes in pregnancies complicated by systemic lupus erythematosus: a population-based study. *J Obstet Gynaecol Can* 2013;35:323–28.

13. Cortés-Hernández J, Ordi-Ros J, Paredes F, et al. Clinical predictors of fetal and maternal outcome in systemic lupus erythematosus: a prospective study of 103 pregnancies. *Rheumatology* 2002;41:643–50.

14. Chakravarty EF, Colón I, Langen ES, et al. Factors that predict prematurity and preeclampsia in pregnancies that are complicated by systemic lupus erythematosus. *Am J Obstet Gynecol* 2005;192:1897–904.

15. Clowse ME, Jamison M, Myers E, et al. A national study of the complications of lupus in pregnancy. *Am J Obstet Gynecol* 2008;199:127.e1–6.

16. Clowse ME. Lupus activity in pregnancy. *Rheum Dis Clin North Am* 2007;33:237–52. [Review]

17. Kamen DL, Barron M, Parker TM, et al. Autoantibody prevalence and lupus characteristics in a unique African American population. *Arthritis Rheum* 2008;58:1237–47.

18. Pollitzer WS. The Gullah people and their African heritage. University of Georgia Press, 1999.

19. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. *Arthritis Rheum* 1982;25:1271–7.

20. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. *Arthritis Rheum* 1997;40:1725.

21. Frösten JF, Gordijn SJ, Abeln-Alex H, et al. Making stillbirths count, making numbers talk—in data collection for stillbirths. *BMC Pregnancy Childbirth* 2009;9:58.

22. Gladman DD, Goldsmith CH, Urowitz MB, et al. The Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) Damage Index for Systemic Lupus Erythematosus International Comparison. *J Rheumatol* 2000;27:373–6.

23. Lazo R, Guevara M, Pérez P, et al. Lupus nephritis prevalence, clinical course and treatment. *Drugs Aging* 2007;24:701–15.

24. Frösten JF, Gordijn SJ, Abeln-Alex H, et al. Making stillbirths count, making numbers talk—in data collection for stillbirths.

25. Zanolli C, Zadik A, et al. Pregnancy and autoimmune disease: a national study of the Hopkins Lupus Cohort. *Obstet Gynecol* 2011;118:433–43. [Review]

26. Buyon JP, Clancy RM, Friedman DM. Cardiac manifestations of neonatal lupus erythematosus: guidelines to management, integrating clues from the bench and bedside. *Nat Clin Pract Rheumatol* 2009;5:139–48.

27. Kiyutti J, Hartikainen-Sorri AL, Makitalo R. Occurrence of antinuclear antibodies in an unselected pregnancy population. *Gynecol Obstet Invest* 1992;33:21–5.

28. Seibold JR. Mitochondrial DNA (mtDNA) haplotypes reveal maternal population genetic affinities of lupus.

29. Weitgasser R, Spitzer D, Kartnig I, et al. Measurement of increases in anti-double stranded DNA antibody levels as a predictor of disease exacerbation in systemic lupus erythematosus: a long-term, prospective study. *Arthritis Rheum* 1990;33:634–43.

30. Cheong HN, Chen Y, et al. Association of mitochondrion DNA and pregnancy loss. *Pregnancy Childbirth* 2012;73:186–91.

31. Arnett FC, Edworthy SM, et al. The 1988 American Rheumatism Association revised criteria for the classification of systemic lupus erythematosus. *Arthritis Rheum* 1988;31:315–24.

32. Terasawa T, Yoshizumi T, et al. Mitochondrial DNA haplotypes predict lupus susceptibility in a Japanese population. *J Rheumatol* 2008;35:1765–71.

33. Krumholz EA, Katz JN, et al. A meta-analysis of pregnancy outcomes in patients with systemic lupus erythematosus and lupus nephritis. *Arthritis Rheum* 2012;64:2311–18.

34. Smith A, Oliveira GH, Lahr BD, et al. A systematic review and meta-analysis of pregnancy outcomes in patients with systemic lupus erythematosus and lupus nephritis. *Clin J Am Soc Nephrol* 2010;5:2060–8. [Review]

35. Do Prado AD, Paveson DM, Staub HL, et al. Association of anticardiolipin antibodies with preeclampsia: a systematic review and meta-analysis. *Obstet Gynecol* 2011;118:433–43. [Review]

36. Buyon JP, Clancy RM, Friedman DM. Cardiac manifestations of neonatal lupus erythematosus: guidelines to management, integrating clues from the bench and bedside. *Nat Clin Pract Rheumatol* 2009;5:139–48.

37. Kiyutti J, Hartikainen-Sorri AL, Makitalo R. Occurrence of antinuclear antibodies in an unselected pregnancy population. *Gynecol Obstet Invest* 1992;33:21–5.

38. Weitgasser R, Spitzer D, Kartnig I, et al. Association of HELLP syndrome with autoimmune antibodies and glucose intolerance. *Diabetes Care* 2000;23:786–90.

39. Yamamoto T, Yoshimura S, Geshi Y, et al. Antis-sDNA and dsDNA antibodies in preeclampsia. *Asia-Oceania J Obstet Gynaecol* 1994;20:93–9.

40. Terborg EJ, Horst G, Hummel EJ, et al. Measurement of increases in anti-double stranded DNA antibody levels as a predictor of disease exacerbation in systemic lupus erythematosus: a long-term, prospective study. *Arthritis Rheum* 1990;33:634–43.

41. To CH, Petri M. Is antibody clustering predictive of clinical subsets and damage in systemic lupus erythematosus? *Arthritis Rheum* 2005;52:4003–10.

42. Clowse ME, Magder LS, Petri M. The clinical utility of measuring complement and anti-DNA antibodies during pregnancy in patients with systemic lupus erythematosus. *J Rheumatol* 2011;38:1012–16.

43. Devoe LD, Loy GL. Serum complement levels and perinatal outcome in pregnancies complicated by systemic lupus erythematosus. *Obstet Gynecol* 1984;63:796–800.

44. Abramson SB, Buyon JP. Activation of the complement pathway; comparison of normal pregnancy, preeclampsia, and systemic lupus erythematosus during pregnancy. *Am J Reprod Immunol* 1992;28:183–7.

45. Djordjevic S, O’Connell C, et al. Derivation of the SLEDAI: a disease activity index for lupus patients. *Arthritis Rheum* 1992;35:580–8.